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Portal vein embolisation (PVE) is used to increase the remnant liver volume before major liver resection for colorectal metastases. The
resection rate after PVE is 60–70%, mainly limited by disease progression. The effect of PVE on tumour growth rate has not been
investigated. The objective of this study was to compare the growth characteristics of resected colorectal liver metastases in patients
undergoing pre-operative PVE with those of matched controls who had not undergone PVE. There were 22 patients who had
undergone preoperative PVE and 20 matched controls. Tumour growth rate was calculated by the change in tumour volume (CT/MRI
volumetric assessment) from diagnosis to resection. Resected histological specimens were examined by two histopathologists
independently for cell differentiation, percentage tumour cell necrosis and mitotic rate. Immunochemical staining with Ki67 was carried
out using the MIB-1 monoclonal antibody and quantified using a Glasgow cell-counting graticule. The groups were comparable in
demographics, stage of primary disease, volume of liver metastases at presentation and chemotherapy received. The tumour growth
rate calculated from imaging was more rapid in the PVE group compared with that in controls (control: 0.05±0.25mlday
 1,P V E :
0.36±0.68mlday
 1, P¼0.06). Histology showed no difference in the degree of differentiation, extent of necrosis or apoptosis between
the two groups. However, mitotic rate was higher post PVE, as was the proliferation index Ki67 (P¼0.04). This study has confirmed that
tumour growth rate increased following PVE and that this is related to increased tumour cell division.
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Portal vein embolisation (PVE) is an established technique to
achieve curative resection in patients who would otherwise be
advised against surgery due to an anticipated inadequate residual
liver volume. The resection rate after PVE is 60–70%, mainly
limited by disease progression (Mueller et al, 2008; Pamecha et al,
2009). This may reflect either a rapid disease progression in
patients who are selected for PVE or that PVE stimulates tumour
growth. Tumour growth exceeding that of the normal liver
parenchyma has been shown on imaging following PVE in patients
with contra lateral lobe metastases (Elias et al, 1999), and the
tumour-doubling time following PVE has been shown to be
reduced from 92 to 76 days (Kokudo et al, 2001). There have been
concerns that PVE may increase the risk of disease recurrence after
curative resection (Kokudo et al, 2001; Pamecha et al, 2009). The
influence of PVE on tumour growth characteristics on resected
cancers has not been investigated. This study was designed to
evaluate the effect of PVE on tumour growth and cancer-cell
proliferation in patients with resected colorectal liver metastases.
MATERIALS AND METHODS
The study involved 22 patients who had undergone liver resection
and had required PVE due to an inadequate anticipated residual
liver volume. Over the study period (September 1999 to September
2005), 109 patients underwent major liver resection (X3 liver
segments) for colorectal cancer (CRC) metastases at the centre.
Eighty-seven of these patients underwent liver resection without
PVE. Twenty of these 87 patients had similar tumour volumes at
presentation compared with the patients undergoing PVE and were
therefore selected as a non PVE control group. Clinical details of
the patients were collected prospectively, including demographics,
stage of the primary disease, details of the liver metastases and
chemotherapy received.
Volumetric measurements and tumour growth rate
analysis
Tumour volumes were measured by CT (GE Medical Systems
High Speed System, Milwaukee, WI, USA) or MRI (Philips Intera
1 T System Philips, Netherlands) at the time of diagnosis.
The technique for measuring volumes has been described earlier
(Beal et al, 2006). Briefly, axial 10-mm sections through the liver
were obtained in a single breath-hold. Using a workstation, the
tumour volume was calculated by multiplying the area of each liver
image by the slice thickness. An experienced hepato-biliary
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sradiologist performed all the measurements. The tumour volume
was also calculated from the resected specimen by measuring the
three dimensions of the tumour and calculating the volume.
Tumour growth was calculated (mlday
–1) by subtracting the
tumour volume at diagnosis from the volume at resection and
dividing by time in days. The growth rate between the two groups
was compared.
Histological analysis
Resected specimens were sliced and fixed in 10% formalin for 24h.
Protocol samples were paraffin processed and tissue sections were
prepared using routine laboratory standard procedures and
stained with haematoxylin and eosin. The predominant cellular
differentiation and the percentage of necrosis were identified.
The mitotic index and apoptotic counts were calculated in 10
high-power fields of viable tumour.
Immunohistochemistry
Proliferative activity of the tumours was assessed by using the
mouse antihuman monoclonal Ki67 antibody (clone MIB-1)
obtained by DAKO (Glostrup, Denmark). The antibody reacts
with human Ki67 nuclear antigen which is only expressed during
cell division. Sections of formalin-fixed, paraffin-embedded tissues
(3mm) were cut into charged slides and sections were immuno-
stained as per protocol (microwave antigen retrieval in ethylene
diamine tetraacetic acid (EDTA) buffer for 20min at 850W,
antibody concentration 1 out of 300, Novolink Polymer Detection
System, Novocastra Vision Byosystems, UK). The labelling index
was determined by using a Glasgow cell-counting graticule (Going,
1994). Areas where labelling was the highest were chosen and
necrotic areas were avoided. The number of Ki67-positive cells
was counted in 10 high-power fields and expressed as a percentage
of the total number of cancer cells. Histological assessment
was carried out by two experienced pathologists (A Levene and
F Grillo) independently, who were blinded to the treatment group
and related clinical data.
Chemotherapy
Of the 22 patients undergoing PVE, all had chemotherapy before
and after the procedure. Chemotherapy post-PVE was started 2
weeks after embolisation and continued for 6 weeks or until a
decision was made regarding liver resection surgery. All 20
patients in the control group received chemotherapy before the
liver resection. Three patients with PVE received chemotherapy
after liver resection because of involved (n¼1) or close (n¼2)
resection margin (13.6%). Two patients without PVE received
chemotherapy after liver resection because of involved (n¼1) or
close (n¼1) resection margin (10%). In all cases, this comprised a
standard 5FU and folinic-acid-based protocol combined with
oxaliplatin or irinotican. The average number of cycles was six.
Statistics
Student t-tests were used to compare the data. Data are expressed
as means with 95% confidence intervals and median with ranges.
Po0.05 was considered significant. Survival rates were calculated
using the Kaplan–Meier methods.
RESULTS
The patient, primary tumour and liver metastases characteristics
are shown in Table 1. The groups were well matched by age, sex,
primary tumour site, Duke’s stage and the temporal relationship of
the liver metastases (synchronous/metachronous) to the presenta-
tion of the primary.
As would be expected the volumes of liver metastases at
presentation in the groups were the same (control: 81.41±57, PVE:
81.3±88, P¼0.98 (Figure 1A)). The tumour volume at resection
was higher in the PVE group, but this was not significant (control:
116±77, PVE: 149±110, P¼0.19) (Figure 1B). The time from
presentation to resection was longer in the PVE group by an
average of 33 days (183±88 vs 150±78, P¼0.19) (Figure 1C). The
tumour growth rate (mlday
–1) was more rapid in the PVE group
compared with controls (control: 0.05±0.25, PVE: 0.36±0.68,
P¼0.06) (Figure 1D).
The morphology of the resected tumours in both groups was
evaluated by assessing tumour differentiation, necrosis and
apoptosis. These variables were not different between the groups
(Table 2). The mitotic rate (Figure 2A) was increased following
PVE as measured by both histopathologists, although statistically
significant for only one (Table 2). The Ki67 proliferation
index increased significantly following PVE (Table 2)
(Figures 2B, 3 and 4).
A subgroup analysis was carried out comparing the tumour
growth and Ki67 in patients with synchronous and metachronous
metastases (Table 3). Growth rate and proliferation index were
increased by PVE in both groups, but was statistically significant
only in the metachronous group.
The 5 year survival of the patient group who had undergone
PVE was 25% compared with 55% for the control group (P¼ns)
(Figure 5).The median disease-free survival of patients undergoing
liver resection following PVE was 12 months, and 24 months in
those resected without undergoing PVE (Figure 6).
DISCUSSION
Liver resection provides the main possibility of cure in patients
with colorectal liver metastases and 5-year survival ranges from 25
to 58% (Simmonds et al, 2006). One of the contraindications to
hepatic resection is a small future liver remnant. The small residual
liver volume can lead to cholestasis, fluid retention, impaired liver
synthetic function and liver failure (Melendez et al, 2001; Schindl
et al, 2005). PVE increases the anticipated future liver volume and
allows surgery in patients who would otherwise be contra-
indicated for resection. The potential disadvantage of PVE is that
earlier studies have suggested that it may stimulate tumour growth
and lead to reduced long-term survival (Elias et al, 1999; Kokudo
et al, 2001).
This study has examined the effect of PVE on tumour growth
and morphology. The tumours grew significantly during the period
between diagnosis and resection. The growth rate was significantly
higher following PVE. The control group was well matched by
Table 1 Demographics, primary tumour and liver metastases
characteristics
Control
(n¼20)
PVE
(n¼22)
P-value
Age (range) 61.5 (39–78) 62.5 (46–78) 0.876
Female 9 10 0.724
Dukes (B/C) 4/16 5/17 0.754
Rectal/colon 6/14 9/13 0.213
Syn/Meta 10/10 13/9 0.537
Ext Rt / Rt Hep 8/12 14/8 0.548
Number of tumours 2 (1–5) 3 (1–9) 0.153
Resection margin (mm) 20.2±3.7 14.7±4.2 0.338
Number of chemotherapy cycles 6 (3–10) 6 (3–10) 0.141
Syn¼synchronous; Meta¼metachronous; Ext Rt¼extended right hepatectomy; Rt
Hep¼right hepatectomy;PVE¼portal vein embolisation.
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stumour stage and burden;although the period between initial
diagnosis and resection was longer for the PVE group (by 33 days),
this was not statistically significant. This would suggest that PVE
stimulates tumour growth. Any difference in the growth rates of
the two groups could have been more effectively addressed by
including a comparison of growth rates before PVE. However,
interim CT scans were not available in the control group . Another
possible explanation for the tumour volume changes following
PVE would be ischemia and inflammation rather than cancer
growth. However, the resected cancers showed no evidence of
haemorrhage and the degree of cell necrosis and apoptosis was
similar with and without PVE.
This is the first study to compare tumour growth from imaging
with increased cancer-cell proliferation at the molecular level
following PVE. The mitotic index is a sensitive but non specific
marker of cell proliferation (Peeters et al, 2006). The mitotic index
was increased in blinded assessment by both histopathologists
but was statistically significant for one observer only. This inter-
observer variation in the mitotic index can be explained by
difference in appreciation of dividing cells by the two histopatho-
logists. The Ki67 has been shown to be more specific in assessing
the cancer-cell proliferation rate (Peeters et al, 2006). The Ki67
labelling index was significantly higher in the PVE group than
controls. A high Ki67 labelling index is an adverse prognostic
factor in patients undergoing hepatectomy for colorectal liver
metastases (Weber et al, 2001). Identification of the Ki67 labelling
index before and after PVE in the same patient would have been of
interest, but pre-PVE biopsy was not carried out for ethical reasons
as it carries a risk of tumour seeding.
A subgroup analysis of patients with synchronous and
metachronous metastases showed tumour growth rate and Ki67
to be greater post PVE for the latter. The reason for this has not
been established and should be the subject of further study. It is
possible that there is a biological difference between these tumours
which allows PVE to have a more marked effect on growth with
metachronous disease.
The increase in tumour growth following PVE could be
secondary to haemodynamic changes. Portal vein embolisation
increases hepatic arterial blood flow (Nagino et al, 1998; Denys
et al, 2000; Yokoyama et al, 2007). As intrahepatic metastases
depend solely on arterial blood supply (Archer and Gray, 1989),
increased hepatic arterial flow may provide nutritional advantages
for tumour growth. A correlation between tumour growth rate and
arterial flow to the liver could clarify these hypotheses.
Tumour growth could be initiated by a reduction in cell apoptosis
or increase in cell division (Peeters et al, 2006). Several cytokines
and growth factors are known to play important roles in liver
regeneration (Kusaka et al, 2006; Yokoyama et al,2 0 0 7 ) ,a n dc o u l d
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Figure 1 (A) Tumour volume at diagnosis. (B) Tumour volume at resection. (C) Time difference from diagnosis to resection. (D) Tumour growth rate.
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sincrease tumour growth after PVE. Mueller et al, reported, in a rat
model of portal branch ligation, an association between hepatic
atrophy and increased expression of genes known to promote
tumour growth and angiogenesis (Mueller et al, 2003). Expression of
hepatocyte growth factor (HGF)-mRNA is markedly increased after
portal vein ligation (Uemura et al, 2000), which is known to
stimulate growth of colorectal carcinoma cells in vitro (Ueno et al,
1996; Nabeshima et al, 1998). Negative regulators of hepato-
cyte proliferation, such as transforming growth factor (TGF)-b1
(Braun et al, 1988; Kusaka et al, 2006), are strongly expressed in the
ligated lobe (Uemura et al, 2000; Kusaka et al, 2006) and these may
contribute to increased cancer-cell proliferation.
The survival analysis showed excellent long-term survival in
patients undergoing major liver resection for CRC metastases with
Figure 3 Typical example of mitosis expression (dark brown stain) in CRC metastases for a patient who had not undergone PVE (A) compared with that
post PVE (B), suggesting high cancer-cell proliferation post PVE.
Table 2 Tumour morphology with and without PVE
Control
(n¼20)
PVE
(n¼22)
P-value
Necrosis (%)
Median 35 (15–95) 45 (10–95)
Mean±s.d. 39.5±4.9 37.7±4.8 0.801
Apoptosis/10hpf
Median 188 (54–327) 132 (68–350)
Mean±s.d. 178±87 147±69 0.212
Mitotic count/10hpf
Observer 1
Median 9 (3–19) 11 (4–22) 0.404
Mean±s.d. 10.5±1.0 11.8±1.1
Observer 2
Median 9 (3–24) 14 (3–35)
Mean±s.d. 9.7±5.0 16.1±8.8 0.009
Ki67 (%)
Observer 1
Median 29 (3–48) 36 (6–75)
Mean±s.d. 22.6±2.2 36.7±3.8 0.048
Observer 2
Median 38(11–62) 47(15–93)
Mean±s.d. 37.8±13.8 48.9±18.9 0.046
PVE¼portal vein embolisation.
A
B
Control Ob1 PVE Ob1 Control Ob2 PVE Ob2
Control Ob1 PVE Ob1 Control Ob2 PVE Ob2
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Figure 2 Mitotic count and Ki67 by two independent pathologists. (A)
Mitotic count. (B) Ki67 count.
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sa 55% 5-year survival for the control (no PVE) group. This figure
compares favourably with reports from other centres suggesting a
high-quality oncological surgery (Simmonds et al, 2006). The PVE
group, despite having resection with clear margins, had a lower
disease-free and long term survival. As the patient groups were
well matched for cancer stage, this would strongly support the
molecular evidence that PVE stimulates cancer cell division and, as
a result, is associated with a reduced long term outcome.
In the present study, tumour growth was observed in patients
following PVE despite pre- and post-PVE chemotherapy. Although
pre- and-post operative chemotherapy may provide a small survival
advantage, this should be short course and should avoid delaying
surgical intervention (Nordlinger et al, 2007). In the light of increased
hepatic arterial flow following PVE, which may be contributing to
tumour growth, there is a logical reason for anti-angiogenic agents,
such as Bevacizumab, along with routine chemotherapy (Hurwitz
et al,2 0 0 5 ;S a l t zet al, 2007) to cover the peri PVE period. This
possibility requires evaluation in a prospective study.
In conclusion, although PVE appears to benefit patients by
facilitating liver resection in those who would be considered
inoperable because of insufficient future liver remnant volume,
Figure 4 Typical example of Ki67 expression (dark brown stain) in CRC metastases for a patient who had not undergone PVE (A) compared with that
post PVE (B), suggesting high cancer-cell proliferation post PVE.
Table 3 Subgroup analysis of tumour growth rate and Ki67 for
synchronous and metachronous colorectal liver metastases
Control PVE P-value
Tumour growth rate (mlday
–1)
Metachronous n¼10 n¼9
Median  0.08 ( 0.57–0.07) 0.42 ( 1.2–2.0)
Mean±s.d.  0.15±0.22 0.41±0.88 0.06
Synchronous n¼10 n¼13
Median 0.09 ( 0.26–0.66) 0.51 ( 1.1–1.0)
Mean±s.d. 0.01±0.26 0.28±0.59 0.15
Ki 67(%)
Metachronous n¼10 n¼9
Median 21.85 (3.8–35.8) 37.40 (6.9–75)
Mean±s.d. 21.8±10.5 41.5±20.4 0.01
Synchronous n¼10 n¼13
Median 31.9 (28.1–48.5) 34 (11.9–61)
Mean±s.d. 33.3±6.1 34±13.4 0.89
PVE¼portal vein embolisation.
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Figure 5 Disease-free survival after liver resection for colorectal metastases
with and without prior PVE.
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Figure 6 Overall survival after liver resection for colorectal metastases
with and without prior PVE.
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sthere are concerns of stimulated tumour growth and inferior long
term survival. Patients for PVE should be selected carefully and PVE
should be avoided in patients with an adequate future liver remnant.
At present, selection of patients for PVE is based on CT/MRI
volumetry, and 30% of future liver remnant volume is considered
adequate in patients with normal liver and 40% in patients with
abnormal liver function (Abdalla et al, 2001). Incorporating hepatic
functional studies, such as hepatic scintigraphy (Dinant et al,2 0 0 7 )
and biopsy of normal liver, to evaluate histological abnormality
(steatosis, steatohepatitis and cholestasis) in patients with border-
line future liver remnant will provide further information on the
quality of the residual liver and may avoid unnecessary PVE.
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